RGS must have given Edison and update on its near term prospects in Japan, and if those deal metrics discussed in the report are achieved with the sub license partner I expect RGS will be in line for a substantial re-rate.
This imminent catalyst also explains why RGS's Japan based director bought over one million shares on market recently.
It is also good to read that partnering discussions for Sygenus are progressing well.
Also good to read that pre-climical studies have started with RGSH4K and an anti PD1 inhibitor.
RGS Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
